AIM ImmunoTech (AIM) Company Overview

Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of Ampligen as an intranasal adjuvant increased immune response, including cross-protection via avian influenza antibody generation in humans Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of Ampligen as an intranasal adjuvant increased immune response, including cross-protection via avian influenza antibody generation in humans

KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) has confirmed its progress toward the close for the Tulu Kapi Gold project financing, ahead of a full project launch. The AIM-quoted mine developer said that its secured lenders have increased project financing facilities to $240 million, from $190 million.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE A PROSPECTUS OR OFFERING MEMORANDUM OR AN OFFER FOR SALE OR SUBSCRIPTION IN RESPECT OF ANY SECURITIES IN THE COMPANY.

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) is teaming up with SimonMed Imaging, one of America's largest outpatient medical imaging providers. It will see the AIM-quoted firm's Xenon MRI platform delivered across the SimonMed network – starting with a site in Scottsdale, Arizona, later this year.

OCALA, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final Clinical Study Results for the “Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions” (“AMP-518”) was posted yesterday to ClinicalTrials.gov (See: NCT05592418 ).

Shares in Deltex Medical Group plc (AIM:DEMG) (AIM: DEMG) fell 50% following the announcement of a proposed delisting from AIM and leadership changes. The company attributed its decision to delist to the high costs of maintaining its AIM listing, estimated at £200,000 annually, representing 10% of its unaudited 2024 revenues of £2.1 million.

– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces

Plantible is a vertically integrated biology company unlocking the potential of duckweed to create a plant-based protein that emulates the characteristics of animal-based proteins CH4 Global is scaling up production of Asparagopsis seaweed to reduce enteric methane emissions from cattle, a key driver of climate change NEWPORT BEACH, Calif. , Jan. 15, 2025 /PRNewswire/ -- Chipotle Mexican Grill (NYSE: CMG) today announced it is making minority investments in Plantible, a company harnessing the power of Lemna, an aquatic plant, to create what could prove to be the world's most functional plant-based protein, and CH4 Global, a company aiming to impact climate change at scale via methane-reducing innovations.